Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome
Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome
复制标题
使用多巴胺激动剂治疗围产期心肌病和随后的妊娠取得满意的结果
DOI：
--
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
R. Carvalho
中科院分区：
文献类型：
--
作者：
M. A. Melo;Jordão Sousa Carvalho;F. Feitosa;E. Araújo Júnior;A. Peixoto;Francisco Herlânio Costa Carvalho;R. Carvalho
摘要围产期心肌病的病理生理机制尚未完全确定，尽管与包括先兆子痫在内的各种已知因素有很强的相关性。围产期心肌病治疗遵循与心力衰竭伴收缩功能障碍相同的建议。临床和实验研究表明，催乳素降解产物可诱发这种心肌病。D2多巴胺受体激动剂溴隐亭和卡麦角林对催乳素产生的药理学抑制已证明在治疗反应方面具有令人满意的结果。在这里，我们介绍了一名第一次怀孕的青少年患者的病例，她患有围产期心肌病，在服用卡麦角林（用作心功能障碍治疗的辅助药物）后，左心室功能发展正常。随后，尽管两次妊娠之间的间隔很短，但患者在整个妊娠期或新妊娠的产褥期表现出令人满意的进展，没有任何心脏改变。在治疗围产期心肌病病例时，应考虑口服多巴胺激动剂，并且在大多数三级中心，特别是在发展中国家，可以负担得起。
Abstract Pathophysiological mechanisms of peripartum cardiomyopathy are not yet completely defined, although there is a strong association with various factors that are already known, including pre-eclampsia. Peripartum cardiomyopathy treatment follows the same recommendations as heart failure with systolic dysfunction. Clinical and experimental studies suggest that products of prolactin degradation can induce this cardiomyopathy. The pharmacological suppression of prolactin production by D2 dopamine receptor agonists bromocriptine and cabergoline has demonstrated satisfactory results in the therapeutic response to the treatment. Here we present a case of an adolescent patient in her first gestation with peripartum cardiomyopathy that evolved to the normalized left ventricular function after cabergoline administration, which was used as an adjuvant in cardiac dysfunction treatment. Subsequently, despite a short interval between pregnancies, the patient exhibited satisfactory progress throughout the entire gestation or puerperium in a new pregnancy without any cardiac alterations. Dopamine agonists that are orally used and are affordable in most tertiary centers, particularly in developing countries, should be considered when treating peripartum cardiomyopathy cases.
登录
查看更多内容
影响因子：
24
作者：
McNamara DM;Elkayam U;Alharethi R;Damp J;Hsich E;Ewald G;Modi K;Alexis JD;Ramani GV;Semigran MJ;Haythe J;Markham DW;Marek J;Gorcsan J 3rd;Wu WC;Lin Y;Halder I;Pisarcik J;Cooper LT;Fett JD;IPAC Investigators
通讯作者：
IPAC Investigators
影响因子：
24
作者：
Bello, Natalie;Rendon, Iliana S. Hurtado;Arany, Zoltan
通讯作者：
Arany, Zoltan
影响因子：
64.5
作者：
Hilfiker-Kleiner, Denise;Kaminski, Karol;Drexler, Helmut
通讯作者：
Drexler, Helmut
影响因子：
64.8
作者：
Patten, Ian S.;Rana, Sarosh;Shahul, Sajid;Rowe, Glenn C.;Jang, Cholsoon;Liu, Laura;Hacker, Michele R.;Rhee, Julie S.;Mitchell, John;Mahmood, Feroze;Hess, Philip;Farrell, Caitlin;Koulisis, Nicole;Khankin, Eliyahu V.;Burke, Suzanne D.;Tudorache, Igor;Bauersachs, Johann;del Monte, Federica;Hilfiker-Kleiner, Denise;Karumanchi, S. Ananth;Arany, Zoltan
通讯作者：
Arany, Zoltan
影响因子：
9.5
作者：
Haghikia A;Podewski E;Libhaber E;Labidi S;Fischer D;Roentgen P;Tsikas D;Jordan J;Lichtinghagen R;von Kaisenberg CS;Struman I;Bovy N;Sliwa K;Bauersachs J;Hilfiker-Kleiner D
通讯作者：
Hilfiker-Kleiner D